Aug 17, 2019
In 1998, Maitake Products, Inc., Ridgefield Park, NJ, proudly announced that the company has obtained its IND (Investigational New Drug Application) from the FDA to conduct a Phase II pilot study on the effect of Maitake Mushroom D-fraction Extract (D-fraction) on advanced breast and prostate cancer patients. The researchers at New York Medical College, Valhalla, NY, in 2002 announced the results of their study of comparing effects of various mushroom extract products as well as ß-glucan products on the U.S. and Japanese market against prostate cancer cells (PC-3; the most aggressive with metastasis cancer cells) in vitro. Maitake mushroom has shown the most potent cytotoxic effect.
The unique protein-bound polysaccharide compound found in Maitake mushroom based on 1,3 and 1,6 Beta glucans has been marketed as a dietary supplement both in the USA and Japan since 1995 and has demonstrated clinical effectiveness in enhancing immune system function particularly in those patients with various forms of cancers, HIV/AIDS and chronic fatigue syndrome.
Disturbing fact is that according to the survey done just in USA approximately 181,000 new cases of breast cancer develop each year and over 40,000 women die of it annually.
Prostate cancer is now the most frequently diagnosed malignancy in the USA with over 120,000 new cases and 32,000 deaths occurring annually (which is the second leading causes of male mortality due to cancer). The statistics in other countries around the world are just as alarming!
Protein - 22.25%
Amino acid - 23.58%
Rich in minerals such as Zn and Se
Polysaccharide (23 fractions)